AMIX — Autonomix Medical Income Statement
0.000.00%
Last trade - 00:00- $5.59m
- -$3.55m
Annual income statement for Autonomix Medical, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 13.4 | 1.99 | 12 | 11.6 |
| Operating Profit | -13.4 | -1.99 | -12 | -11.6 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -13.3 | -1.99 | -15.4 | -11.4 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -13.3 | -1.99 | -15.4 | -11.4 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -13.3 | -1.99 | -15.4 | -11.4 |
| Adjustments to Net Income | ||||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -12.8 | -1.99 | -15.4 | -11.4 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -12.3 | -1.89 | -16.4 | -6.46 |